Jennifer Carver - La Jolla Senior Vice President Operations
| LJPCDelisted Stock | USD 6.22 0.00 0.00% |
President
Ms. Jennifer A. Carver is the Chief Operating Officer of the Company. Prior to her appointment as Chief Operating Officer, Ms. Carver held a number of operational roles of increasing responsibility since joining the Company in February 2014, most recently as Senior Vice President, Operations of the Company. Ms. Carver has more than 20 years of crossfunctional leadership experience in pharmaceutical drug development and the healthcare industry. Prior to joining La Jolla, Ms. Carver was Senior Director of Project Management at Spectrum Pharmaceuticals, Inc., leading the NDA and launch activities for Beleodaq, an FDAapproved, anticancer agent, from 2012 to 2014. Previously, she held various roles at Allos Therapeutics, Inc. from 2001 to 2012, including Project Manager for Folotyn, an FDAapproved, anticancer agent, and leading integration activities following the acquisition of Allos by Spectrum Pharmaceuticals in 2012 since 2017.
| Age | 63 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 617 715-3600 |
| Web | www.ljpc.com |
La Jolla Management Efficiency
The company has return on total asset (ROA) of 1.64 % which means that it generated a profit of $1.64 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0544 %, meaning that it created $0.0544 on every $100 dollars invested by stockholders. La Jolla's management efficiency ratios could be used to measure how well La Jolla manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 124.8 M in liabilities with Debt to Equity (D/E) ratio of 7.16, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. La Jolla Pharmaceutical has a current ratio of 3.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist La Jolla until it has trouble settling it off, either with new capital or with free cash flow. So, La Jolla's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like La Jolla Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for LJPC to invest in growth at high rates of return. When we think about La Jolla's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Mark Monroe | Transocean | 63 | |
| Bradley Alexander | Transocean | N/A | |
| Allan Hughes | Cirrus Logic | 56 | |
| Jeff Webster | Vishay Intertechnology | 50 | |
| Richard Simoncic | Microchip Technology | 60 | |
| Douglas Carlson | MACOM Technology Solutions | 62 | |
| David Tonnel | Transocean | 54 | |
| Guilherme Coelho | Transocean | N/A | |
| Terry Bonno | Transocean | 59 | |
| Primit Parikh | Transphorm Technology | 52 | |
| Vivek Rajgarhia | MACOM Technology Solutions | 50 | |
| Lars Sjoebring | Transocean | 46 | |
| Brad Fluke | Cirrus Logic | 54 | |
| Johan Vandoorn | Vishay Intertechnology | 67 | |
| Clarence Tse | Vishay Intertechnology | 66 | |
| John Kennedy | MACOM Technology Solutions | 55 | |
| Bill Ambrose | Transocean | N/A | |
| Bradley Fluke | Cirrus Logic | 52 | |
| John Kober | MACOM Technology Solutions | 48 | |
| Jo Benson | Cirrus Logic | 57 | |
| Stephen Hayes | Transocean | N/A | |
Management Performance
| Return On Equity | 0.0544 | |||
| Return On Asset | 1.64 |
La Jolla Pharmaceutical Leadership Team
Elected by the shareholders, the La Jolla's board of directors comprises two types of representatives: La Jolla inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LJPC. The board's role is to monitor La Jolla's management team and ensure that shareholders' interests are well served. La Jolla's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, La Jolla's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Tidmarsh, President CEO, Secretary, Director | ||
| Saiid Zarrabian, Independent Chairman of the Board | ||
| James Rolke, VP of RandD | ||
| Chester Zygmont, Director of Finance | ||
| Craig Johnson, Independent Director | ||
| Jennifer Carver, Senior Vice President Operations | ||
| Robert Rosen, Director | ||
| Lakhmir Chawla, Chief Medical Officer | ||
| Laura Douglass, Independent Director | ||
| Dennis Mulroy, CFO | ||
| Darryl Wellinghoff, Chief Commercial Officer |
LJPC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is La Jolla a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0544 | |||
| Return On Asset | 1.64 | |||
| Profit Margin | 10.08 % | |||
| Operating Margin | 4.68 % | |||
| Current Valuation | 242.85 M | |||
| Shares Outstanding | 27.52 M | |||
| Shares Owned By Insiders | 1.91 % | |||
| Shares Owned By Institutions | 71.79 % | |||
| Number Of Shares Shorted | 202.51 K | |||
| Price To Earning | 38.88 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in LJPC Stock
If you are still planning to invest in La Jolla Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the La Jolla's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |